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Background. Gastrinoma-positive lymph nodes and failed localization of the primary tumor during surgical exploration are
described. Specialists suppose that these lymph nodes are metastases rather than a primary gastrinoma. Methods.C a s er e p o r t
with a ﬁve-year long-term followup. A 60-year-old patient with an conﬁrmed gastrinoma was treated in our department.
All preoperative evaluations including somatostatin-receptor-scintigraphy and F-Dopa PET failed to localize the gastrinoma.
Explorative laparotomy revealed a gastrinoma in two peripancreatic lymph nodes. Despite extensive intraoperative exploration,
no primary gastrinoma could be detected in typical localization. Results. Over a period of 5 years, the patient’s gastrin level stayed
in the normal range and the patient seems to be completely cured. Conclusion. A prophylactic partial pancreatoduodenectomy is
not indicated to avoid recurrence, since complete biochemical cure by local resection of the lymph node gastrinoma is possible.
Copyright © 2009 Bernd Jaenigen et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
In 1955, Zollinger and Ellison described a new syndrome
combining recurrent gastric and duodenal ulcers, excessive
gastric acid secretion, and a noninsulin-secreting pancreatic
tumor [1]. Today’s comprehension of the Zollinger-Ellison-
Syndrome (ZES) is more diﬀerentiated. The ZES has an
incidence of 1 per million inhabitants per year [2]. The
gender proportion shows a slight advantage in favour of the
male. More than 90% of patients with ZES typically develop
multiple gastric or duodenal ulcers, preferably located in the
bulbus duodeni or the stomach. Abdominal pain (75–90%)
and diarrhea (40–73%) are the most common symptoms
[3]. Pyrosis (40–60%), nausea (28%), vomiting (26%), and
weight loss (17%) are further typical clinical symptoms [4].
Only 11% of the patients suﬀered from a single symptom,
and 55% of the patients complain about the combination
of abdominal pain and diarrhea [3]. The ZES can be
divided into two diﬀerent entities. About 62–80% of the
gastrinomas appear sporadically. The other 20–38% are
associated with the hereditary (autosomal-dominant) MEN-
I syndrome [3, 5–7] with additional endocrine tumours of
the parathyroid gland (94%), the pituitary gland (60%),
and the adrenal gland (45%) [8]. Tumour manifestations
are localized mainly in the so-called gastrinoma triangle.
Therearethreemaindiﬀerencesbetweenthetwogastrinoma
entities:
(i) localization of primary tumour [9],
(ii) prognosis [9],
(iii) age of the patients [3, 9].
Sporadic gastrinomas are equally localized in the duodenum
and the pancreas, and are characterized by a solitary lesion
[10]. The peak incidence of the sporadic gastrinoma is
described between 40 and 50 years of age in contrast to
theMEN-I-associatedgastrinoma,whichappearsmorelikely
in younger adults (between 30 and 40 years of age) [9].
The MEN-I-associated gastrinomas are mainly located in the
duodenum [11]. Very often, patients suﬀer from multiple
tumours. Overall, the long-term survival rate is better in
MEN-I-associated gastrinomas [9]. Despite 10-year survival
ratesof86%inmedicallytreatedpatients,completeresection
is associated with a further survival beneﬁt (10-year survival2 Case Reports in Medicine
rate 96%) [12, 13]. After biochemical proof (at least triple
elevated serum gastrin and a positive secretin provocation
test), exact preoperative localization of the tumour and the
exclusion of distant metastases are strongly recommended
before surgery. Several diﬀerent diagnostic techniques are
available. Specialists recommend the endosonography with
a sensitivity of 40–100% as the method of choice for
preoperative localization of the primary tumour in spo-
radic gastrinomas because of lower sensitivity of imaging
techniques like the conventional abdominal ultrasonography
(24–44%), computertomography (27–56%), and MRI (25–
46%) [14–18]. A Somatostatin-receptor scintiscan with a
sensitivity of 27–92% is essential to preoperatively exclude
positive lymph node involvement, liver or distant metastases
[15, 16, 18, 19]. The selective arterial Secretin injection test
(SASI) with a sensitivity of 86–100% is suggested for patients
withMEN-I-associatedgastrinomasorrecurrentdisease[11,
15, 17], but this method can only regionalize the lesion. A
promising new method is the F-Dopa PET. The F-Dopa PET
seems to be superior to the other investigating techniques,
but it is not yet well established [5, 20]. In comparison
with the preoperative localisation, intraoperative localisation
by palpation and intraoperative ultrasonography (IOUS) is
successful in 96% [16].
A review of the literature was performed on the occasion
ofthiscasereportwithtwogastrinoma-positivelymphnodes
without any detected duodenal or pancreatic lesion. This
overview discusses the existence of primary lymph node
gastrinomas and adequate therapy regimens.
2.CaseReport
In October 2003, a 60-year-old patient attended a depart-
ment of internal medicine. The patient complained about
pain in the upper abdominal region. A gastroscopy showed
an extended inﬂammation of the duodenum and in the
esophagus with multiple ulcers. During the hospital stay,
a Forrest Ia bleeding took place in the duodenal region.
The bleeding could be arrested endoscopically by clipping.
A Zollinger-Ellison-Syndrome was suspected because of
the extended duodenal and esophagal inﬂammation with
multiple ulcers. The diagnosis was proven by measuring
elevated values (1528ng/L) of Gastrin (reference range
lower 115ng/L). The duodenal ulcers and the esophageal
inﬂammation healed slowly under therapy with omeprazole.
In order to exclude a MEN-I syndrome, 5-hydroxyindole
acetic acid, parathyroid hormone, prolactine, and ACTH
were determined. All parameters showed normal values.
An abdominal computer tomography was performed to
locate the gastrinoma, but no suspected lesion could be
detected. Additionally, a Somatostatin receptor scintiscan
could also not determine the focus. The patient was pre-
sented in our department to plan further treatment. After
a Dopa PET failed to localize the gastrinoma, an explo-
rative laparotomy was performed in April 2004. First, the
duodenum and the pancreas head were exposed by carrying
out a Kocher’s manoeuvre. Then, the pancreas corpus and
tail were completely mobilized. Palpation and intraoperative
Figure 1: Trabecular epithelial cell proliferation with positive
expression of synatophysin (10x).
ultrasonography showed a normal pancreas without any
suspicious pancreatic tumour. An enlarged lymph node
(1 × 0.5cm) was removed from the retropancreatic region.
Instantaneous section found glandular structures matching
a gastrinoma. Subsequently. a complete lymphadenectomy
of the retropancreatic area and the hepatoduodenal ligament
was performed. A second enlarged lymph node was extir-
pated behind the common bile duct. Finally, a duodenotomy
of pars II was performed. Despite careful examination,
no duodenal lesion could be found and the surgery was
completed.Thehistologyofthespecimenshowedtwolymph
nodes inﬁltrated by a gastrinoma. An immunohistochemical
preparation of the specimen showed a positive expression of
gastrin, cytokeratin, chromogranin, and synaptophysin (see
Figure 1).
The patient recovered well from surgery and was dis-
charged on day 12. In May 2004, the patient underwent a fol-
lowup examination in our endocrinology department. The
serum gastrin was 120ng/L. The patient felt better without
continuing omeprazole medication. Followup examinations
of the patient were performed in the county hospital of
Rottweil every year until the last examination in December
2008. The gastrin value was stable with 117ng/L and a
secretin provocation test was negative, demonstrating a
biochemically cured disease up to now.
3. Discussion
Two pathological studies support the hypothesis that neu-
roendocrine cells exist in lymph nodes of the gastrinoma
triangle in patients without a gastrinoma [7, 21].
The existence of primary lymph node gastrinoma as a
cause of Zollinger-Ellison syndrome is, on the other hand,
still controversial. In 1994, Arnold et al. analyzed 110 cases
from 1982 to 1992 [22]. During surgical exploration, 21
patients had a disease limited to the lymph nodes. Explo-
ration included intraoperative ultrasound, endoscopy, and
explorative duodenotomy. All patients underwent a yearly
biochemical and radiological followup. After 5.3 years, 9/21
(43%) patients remained biochemically cured. The other
12 patients showed a biochemically conﬁrmed persistentCase Reports in Medicine 3
or recurrent disease. In 2003, a prospective study of 176
patients with ZES was published. Only tumour-inﬁltrated
lymph nodes were found in 45 cases. Postoperative gastrin
determinations showed biochemical cure in 26/45 (57%)
of the patients. During mean followup of 10.4 years 8/26
(31%) patients had a recurrent disease. Only 18/45 (40%)
patients stayed disease-free. The recurrence rate in the 26
patients with tumour manifestation in more than lymph
node did not diﬀer from that in the 18 patients with one
aﬀectedlymphnode.Accordingtothisstudy,primarylymph
node gastrinomas exist in 10% of the patients and are,
therefore, not a rare entity [23]. Additionally, several case
reports present patients with solitary lymph node tumour
manifestation. In most cases, followup is too short to clarify
the exclusive existence of primary lymph node gastrinoma or
whetherthelymphnodesarealreadymetastasesofverysmall
undetected duodenal gastrinomas [21, 24, 25].
On the other hand, lymph node metastases have no
inﬂuence on the overall survival of the patients with or
without MEN-I. Also, 78% of the MEN-I patients and 52%
of the patients with a sporadic gastrinoma show lymph
node metastases at the time of surgical exploration [9].
In about 19–26%, only gastrinoma-positive lymph nodes
are detected during explorative laparotomy, and despite
extensive surgical treatment, no further tumour in the
pancreas or the duodenum could be localized [5, 12, 26].
After the resection of the lymph nodes, postoperative gastrin
levels normalized in 58–62% of these patients, and it is
assumed that primary lymph node gastrinomas exist as
presented in this case report.
Studies showed that the existence of liver metastasis
decreases the overall 10-year survival rate from 96% to
26–30% [2, 27]. The existence of liver metastasis at ﬁrst
presentation diﬀers between sporadic and MEN-I-associated
gastrinomas (21–2%). The development of metachron liver
metastases is equal in both entities [9]. Liver metastasis
occurred more often with pancreatic than with duodenal
tumours. In 21% of the patients, liver metastases already
existed at the time of ﬁrst diagnosis. The incidence of liver
metastases is closely related to the size of primary tumours
[9]. Primary tumours less than 1cm show a prevalence of
about 4%, tumours between 1 and 2cm of 28% and tumours
larger than 3cm of 62% [27]. Patients, who undergo surgical
resection of the primary tumour, have a signiﬁcant risk
reduction of developing liver metastasis, 3% versus 23%,
compared to medically treated patients [27].
In light of the slow-growing tumour, a followup period
less than 5 years seems to be too short to prove the existence
of primary lymph node gastrinomas.
The aim of surgical exploration is to ﬁnd and remove the
primary tumour and all lymph node and distant metastases.
If we suppose that primary lymph node gastrinoma does
not exist, a curative therapy would be a partial pancreatico-
duodenectomy including a radical lymphadenectomy. But is
such an aggressive therapy justiﬁed, or should the patients
be treated with a restricted procedure and a close-meshed
followup? As is always the case with malignant diseases,
patients can develop distant metastases, for example, in
the liver, limiting the survival rate. On the other hand,
a partial pancreaticoduodenectomy has a high morbidity
rate. These days, a partial pancreaticoduodenectomy is a
highly standardized operative procedure, but even in high-
volume centres, the morbidity rate is still about 40% and
the postoperative mortality rates vary between 1 and 6%. In
over 2/3 of these cases, the complications are directly related
to surgery. Pancreatic leakage with 2–14% and postoperative
haemorrhage with 5% are the most common and severe
complications [26, 28–32]. Long-term complications like
diabetes mellitus exist in 27% of the patients undergoing a
pancreatoduodenectomy [33]. Morbidity and mortality of
extensive surgical exploration including Kocher’s manoeu-
vre, duodenotomy, and resection of all known tumour
lesions was reported with 11% and 0% in 1992 [13].
In our opinion, a prophylactic radical resection like a
partial pancreatoduodenectomy with complete clearance of
the gastrinoma triangle should not be performed due to
the high morbidity and mortality. The tumour biology of
gastrinomas allows a conservative procedure with resection
of all known tumor locations and a medical followup in
half-year intervals. In case of a postoperative persistent high
gastrin level, a partial pancreaticoduodenectomy is probably
the treatment of choice.
4. Conclusion
In several patients with a ZES, an explorative laparotomy
does not detect the primary tumour in the duodenum or
the pancreas but just a gastrinoma-positive lymph node.
The existence of a primary lymph node gastrinoma is
still controversial. The assumption of a very small primary
tumour in the duodenal wall, which cannot be detected
during surgery, suggests a partial pancreaticoduodenectomy
as a curative treatment approach. The tumour biology allows
a close-meshed followup and high postoperative morbidity
and mortality of a partial pancreatoduodenectomy need not
be accepted. After limited surgery, a long-term disease-free
period is possible.
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